Genomics & Biological Data

Miescher isolated deoxyribonucleic acid, though the substance remained largely neglected for decades because proteins were assumed to carry hereditary information. The discovery established the molecule that sequencing would later read.

Their experiments demonstrated that purified DNA could change one strain of bacteria into another, the first evidence that DNA transforms the properties of cells. This shifted attention from proteins to DNA as the carrier of genetic information.

Building on Rosalind Franklin's X-ray diffraction images, Watson and Crick described DNA as two complementary nucleotide strands with A pairing to T and C to G, showing how genetic information is physically encoded. The complementary base-pairing principle underpins every later sequencing method and provided the structural basis without which reading or interpreting a genome would not be possible.

Sanger sequenced all the amino acids in insulin, giving the first conclusive evidence that proteins have specific molecular patterns rather than random composition. The achievement laid the conceptual foundation for sequencing biological polymers, including nucleic acids.

After attending Sanger's lectures in 1954, Crick developed and then published the argument that the arrangement of nucleotides in DNA determines the sequence of amino acids in proteins, and hence protein function. This made determining DNA order a central scientific goal.

Wu used DNA polymerase catalysis and specific nucleotide labelling to sequence the cohesive ends of lambda phage DNA. Both elements remain prominent in modern sequencing schemes.

They generalised the location-specific primer extension approach by using synthetic, location-specific primers. This turned a special-case technique into a general-purpose sequencing strategy.

Fiers's group identified and published the first complete gene sequence in 1972 and the complete MS2 genome in 1976, using RNA sequencing methods. It was the first whole genome of any organism to be sequenced.

Their result demonstrated early chemical approaches to reading DNA order. Progress was aided by the concurrent rise of recombinant DNA technology, which allowed DNA samples to be isolated from sources other than viruses.

The technique supplied all DNA components while excluding the reaction of one of the four bases needed to complete the strand. It was the direct precursor to Sanger's chain-termination method.

Working at Harvard, they created a method for rapidly sequencing DNA by chemical modification and cleavage at specific bases, published in 1977. It was one of the first practical rapid sequencing techniques, though it is now largely obsolete.

At the MRC Centre in Cambridge, Sanger adopted a primer-extension strategy based on selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro replication, publishing the same year alongside a competing chemical method from Walter Gilbert and Allan Maxam. Its relative ease and reliability made it the method of choice, dominating from the 1980s to the mid-2000s and earning Sanger his second Nobel Prize.

φX174 became the first complete DNA genome ever determined. It demonstrated that whole genomes, not just fragments, were within reach of the new methods.

The prize recognised their independent contributions to nucleic acid sequencing. It marked institutional acknowledgment that DNA sequencing had become a foundational scientific capability.

Their method transferred DNA molecules from sequencing reaction mixtures onto an immobilising matrix during electrophoresis. It was commercialised as the GATC 1500 sequencer by GATC Biotech and used in the EU genome-sequencing programme, including yeast chromosome II.

PCR provided a simple way to copy a specific stretch of DNA billions of times from a trace sample, becoming an indispensable preparatory step for nearly all subsequent genome sequencing and genetic analysis techniques.

The British geneticist discovered that variable regions of the genome could identify individuals almost uniquely, a technique swiftly adopted in criminal investigations, paternity disputes and immigration cases and still central to forensic genomic analysis.

The 172,282-nucleotide sequence was achieved with no prior genetic profile knowledge of the virus. This marked a turning point by showing sequencing could proceed de novo on a large genome.

The instrument mechanised parts of the sequencing workflow using fluorescence-based detection. It opened the path to industrial-scale sequencing.

The ABI 370 made automated sequencing a commercial product, soon followed by Dupont's Genesis 2000, which used fluorescent labelling to identify all four dideoxynucleotides in a single lane. Commercial automation made large genome projects feasible.

Trials covered Mycoplasma capricolum, Escherichia coli, Caenorhabditis elegans and Saccharomyces cerevisiae at a cost of US$0.75 per base. In parallel, expressed sequence tag sequencing of human cDNA began in Craig Venter's lab to capture the coding fraction of the human genome.

The patent described stepwise sequencing on DNA arrays, including blots and single DNA molecules. Combined with later DNA colony methods, this chemistry underlies Illumina's Hi-Seq sequencers.

The company went on to develop massively parallel signature sequencing in the 1990s, the first of the high-throughput technologies. It was a key corporate origin of next-generation sequencing.

The principle was described in 1993 with improvements published some years later. It has since been used in almost all massively parallel sequencing instruments, including 454, PacBio, IonTorrent, Illumina and MGI.

Craig Venter, Hamilton Smith and colleagues at The Institute for Genomic Research published in Science the 1,830,137-base circular chromosome of Haemophilus influenzae, the first complete genome of a free-living organism and the first published use of whole-genome shotgun sequencing. The approach proved an entire genome could be assembled from short fragments without a prior map, eliminating initial mapping efforts and becoming standard for large genomes, later scaled up for the human genome.

Pyrosequencing offered a real-time, luminescence-based alternative to gel electrophoresis. A parallelised version was later developed by 454 Life Sciences, subsequently acquired by Roche Diagnostics.

The patents covered DNA sample preparation and random surface-PCR arraying methods. Coupled with base-by-base chemistry, these methods are implemented in Illumina's genome sequencers.

Solexa developed a sequencing method using reversible dye-terminator chemistry and engineered polymerases. The company later became part of Illumina, whose platform came to dominate the market.

The score provided a standard measure for assessing sequencer data accuracy. It gained widespread adoption and remains the most common metric for evaluating sequencing platforms.

The Beijing Genomics Institute, later BGI, took responsibility for one per cent of the genome as the only developing-country participant in the international project, a foothold from which China built the world's largest genomics organisation.

Expansion of the multi-genome reference, first published in 2023, continued to reduce the historic bias toward a single individual's DNA in the standard human reference genome, improving variant detection for people of African and other underrepresented ancestries.

The nonprofit founded by 23andMe co-founder Anne Wojcicki won the bankruptcy auction for the genetic testing company, which had collapsed after a major data breach and mounting losses, keeping the genetic data of millions of customers under new ownership.

Roche said it was developing a sequencing approach relying on small molecules. It signalled continued competition to displace incumbent platform chemistries.

The Genome India project, drawing samples from across the country's population diversity, released initial findings intended to build a genomic reference more representative of Indian populations than the largely European-ancestry datasets researchers had relied on before.

The Generation Study, which screens babies for a panel of treatable childhood-onset genetic conditions and stores sequence data for possible later use, widened recruitment across NHS trusts toward its target of 100,000 newborns.

The network, set up to close gaps in sequencing capacity exposed during the COVID-19 pandemic, added partner laboratories across Africa, Asia and Latin America, aiming to speed detection of new pathogen variants and drug-resistant strains.

The Qatar Genome Programme and the Emirati Genome Program expanded population-scale whole genome sequencing aimed at precision medicine and disease prevention, part of a small group of states building national genomic reference datasets of their own citizens.

The Oxford-founded long-read sequencing firm, highly valued at its 2021 listing, restructured operations as revenue growth fell short of expectations, even as its nanopore sequencing technology continued to gain ground in research and clinical settings.

Sequencing capacity built up across African laboratories identified clade Ib mpox spreading from the Democratic Republic of the Congo into neighbouring countries, evidence that fed into the World Health Organization's declaration of a public health emergency.

The Saudi Human Genome Program, part of the kingdom's Vision 2030 healthcare goals, extended sequencing of citizens to build a national database intended to guide precision medicine and screening for genetic disorders common in the population.

The programme, built to reflect the diversity of the US population more broadly than earlier genomic studies, released an expanded dataset including hundreds of thousands of whole genome sequences to registered researchers.

Built from 47 genetically diverse individuals rather than one, the new reference reduced the bias of the original human genome sequence toward a single donor of largely European ancestry, improving analysis accuracy across populations.

The last unresolved portion was sequenced, yielding the fully sequenced standard reference GRCh38.p14 with 3.1 billion base pairs. This closed gaps left by the 2003 draft.

The remainder was divided among a small number of players including PacBio, Oxford, 454 and MGI. The concentration illustrates how narrowly the capability's supply base is held.

Researchers reported the first sequencing of DNA from animal remains over a million years old, the oldest DNA sequenced to date. It extended the temporal reach of the capability into deep prehistory.

NGS surpassed traditional Sanger sequencing as the most popular approach for generating viral genomes. Corporate leaders in high-throughput products at the time included Illumina, Qiagen and ThermoFisher Scientific.

The instrument offered 1 million zero-mode waveguides compared with 150,000 in the PacBio RS II. It substantially raised throughput for long-read sequencing, which allows reads of 20,000 nucleotides or more.

The HiSeq X Ten system, sold as a batch of ten machines, cut sequencing costs roughly a hundredfold within a decade of the Human Genome Project's completion, making population-scale genome sequencing economically feasible for the first time.

The Chinese genomics company took over Complete Genomics, originator of combinatorial probe anchor ligation technology. This gave China an indigenous high-throughput sequencing platform lineage.

The commission reported that GINA and the Health Insurance Portability and Accountability Act did not adequately protect DNA sequencing data. It noted whole-genome data was especially sensitive because it could identify both individuals and their relatives.

The instrument demonstrated single-molecule human genome sequencing. The company went bankrupt in 2012, illustrating the commercial attrition among early high-throughput platforms.

GINA prohibited discrimination on the basis of genetic information in health insurance and employment. It was the first major legal framework addressing the consequences of widespread DNA sequencing.

The initiative offered $10 million to the first team to sequence 100 human genomes in ten days at high accuracy and no more than $10,000 per genome. It set an explicit public benchmark for cheap, fast whole-genome sequencing.

Offering ancestry and health-related genetic reports directly to individuals for a few hundred dollars, the company and its rivals created a mass consumer market for personal genomic analysis outside clinical settings, raising early questions about data use.

Among the first high-throughput systems, it combined an in vitro paired-tag library, emulsion PCR, an automated microscope and ligation-based chemistry. Accuracy exceeded 99.9999% at roughly one-ninth the cost of Sanger sequencing.

The merged company adopted a simpler sequencing-by-synthesis approach acquired with Manteia Predictive Medicine, whose massively parallel technology had been invented in 1997 by Mayer and Farinelli. This rendered MPSS obsolete and set the course for Illumina's later dominance.

A publicly funded international consortium spanning the US, UK, Japan, France, Germany and China completed a sequence begun in 1990, racing a rival private effort by Celera Genomics and producing the reference genome researchers still build on today. The shotgun-based sequence covered about 92% of the genome, leaving the remaining hard-to-read fraction unresolved for nearly two decades.

The Sanger method in industrial form delivered the first human genome, ushering in the age of genomics. The cost was around $100 million per genome, falling to roughly $10,000 by 2011 as radically different approaches reached the market.

MPSS used parallelised, adapter/ligation-mediated, bead-based chemistry and was the first commercially available next-generation sequencing method, although no instruments were sold to independent laboratories. It marked the start of the commercial NGS era, with several mid-to-late-1990s methods reaching commercial sequencers by 2000.